Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03723564 · ClinicalTrials.gov registry record · Phase 1
Serial Amnioinfusions as Regenerative Therapy for Pulmonary Hypoplasia
A Phase 1 study of Lower Urinary Tract Obstructive Syndrome and Renal Failure Congenital, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT03723564 is a Phase 1 study of Lower Urinary Tract Obstructive Syndrome and Renal Failure Congenital that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 40 participants, roughly in line with the 38-participant average among 3 other Lower Urinary Tract Obstructive Syndrome trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT03723564, a Phase 1 study of Lower Urinary Tract Obstructive Syndrome and Renal Failure Congenital, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Congenital lower urinary tract obstruction (LUTO) is a heterogeneous group of congenital anomalies that lead bladder outlet obstruction. If a complete obstruction is present, the perinatal mortality is estimated to be as high as 90% because of severe pulmonary hypoplasia due to the lack of amniotic fluid. Survivors have significant risk of renal impairment (90%) requiring dialysis or renal transplantation if no fetal intervention is performed. Renal agenesis is the congenital absence of one or both kidneys due to complete failure of the kidney to form. As many as 33% of fetuses with bilateral renal agenesis are stillborn, and the rest of them die immediately after birth due to severe pulmonary hypoplasia. The objective of the serial amnioinfusions for fetuses with these conditions will be to reduce the severity of pulmonary hypoplasia (regenerating the lung functionality) and therefore increase the chance that the newborn survives to begin peritoneal dialysis. Although there is initial evidence that serial amnioinfusions are feasible for the pregnant women and the fetuses, there is still a need to have a prospective clinical trial to confirm the hypothesis that serial amnioinfusions could prevent severe pulmonary hypoplasia allowing the newborns with bilateral renal agenesis or severe LUTO to survive to begin peritoneal dialysis. Therefore, the investigators aim to study the hypothesis that serial amnioinfusions for fetuses with severe LUTO and renal failure and those with bilateral renal agenesis will reduce the severity of pulmonary hypoplasia and therefore increase the chance that the newborn survives to begin peritoneal dialysis.
Conditions Studied
Interventions
- DRUG Lactated Ringers Solution for Injection
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03723564
The ClinicalTrials.gov registry entry for NCT03723564 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 38-participant average among 3 other Lower Urinary Tract Obstructive Syndrome trials with a reported enrollment target. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Lower Urinary Tract Obstructive Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Lactated Ringers Solution for Injection is the first listed.
NCT03723564 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT03723564 about?
NCT03723564 is a clinical study titled "Serial Amnioinfusions as Regenerative Therapy for Pulmonary Hypoplasia". Congenital lower urinary tract obstruction (LUTO) is a heterogeneous group of congenital anomalies that lead bladder outlet obstruction. If a complete obstruction is present, the perinatal mortality is estimated to be as high as 90% because of severe pulmonary hypoplasia due to the lack of amniotic ...
What is the current status of trial NCT03723564?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2018-10-01. Estimated completion is 2027-12-31.
What conditions does trial NCT03723564 study?
This clinical trial studies the following conditions: Lower Urinary Tract Obstructive Syndrome, Renal Failure Congenital, Congenital Renal Anomaly Nos, Renal Agenesis and Dysgenesis.
What interventions are being tested in trial NCT03723564?
The interventions under investigation include: Lactated Ringers Solution for Injection (DRUG).
Who is sponsoring clinical trial NCT03723564?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03723564 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lower Urinary Tract Obstructive Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Lower Urinary Tract Obstructive Syndrome
All registered trials for this condition
Renal Failure Congenital
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.